Understanding Cerebral Malaria using 3D Blood-Brain Barrier models (Mal3D-BBB)

Malaria is a major public health problem and it still causes more than 400,000 deaths per year. CM is one of the most serious complications, with 20% mortality rates even after administration of fast-acting antimalarials. CM pathology is characterized by sequestration of P. falciparum-infected red blood cells (iRBC) in the brain microvasculature, blood-brain barrier (BBB) disruption, and brain swelling.
The current knowledge of CM is primarly based on autopsy studies, because of the absence of suitable animal models. However, there are numerous pathogenic aspects that cannot be studied from post-mortem samples, such as disease progression. In Mal3D-BBB, we bypass these limitations by recreating the human CM pathology with cutting-edge in vitro bioengineering approaches. Rather than using 2D endothelial monolayers, we will develop BBB models with 3D tubular geometry that incorporate multiple cell types: brain microvascular endothelial cells, astrocytes and pericytes. We will mimic vessel dimensions and flow dynamics of the brain vasculature with the goal to recreate physiological BBB permeability rates. Using such technology brings a unique angle to malaria research to evaluate in a controlled and systematic way 1) the molecular mechanisms of BBB disruption after P. falciparum sequestration, and 2) whether parasite and host factors synergize to increase pathology. The findings obtained by this cutting-edge technology will be further validated in samples from CM patients, whose neurovascular pathology has been thoroughly characterized using MRI.
The approach aims to provide a holistic understanding of CM malaria pathogenesis. In return, this knowledge will identify new pathways that could be counteracted to develop therapies to reduce patient mortality. In a broader context, we will build an innovative platform that captures the complex physiology of the BBB, and can be translated to the study of other neurovascular diseases.

European Commission Project details

Enabling Technologies & Assays

May 2021 — Apr 2026

$1.7M

Germany